• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
guides & guidelines

Hydroxyurea Therapy in the Management of Sickle Cell Disease: Evidence-based Management of Sickle Cell Disease

key information

source: National Heart, Lung, and Blood Institute (U.S.)

year: 2014

summary/abstract:

Hydroxyurea Treatment Recommendations: Educate all patients with sickle cell anemia (SCA) and their family members about hydroxyurea therapy (see consensus treatment protocol below). (Consensus–Panel Expertise) In adults with SCA who have three or more sickle cell-associated moderate to severe pain crises in a 12-month period, treat with hydroxyurea. (Strong Recommendation, High-Quality Evidence) In adults with SCA who have sickle cell-associated pain that interferes with daily activities and quality of life, treat with hydroxyurea. (Strong Recommendation, Moderate-Quality Evidence) In adults with SCA who have a history of severe and/or recurrent acute chest syndrome (ACS), treat with hydroxyurea.* (Strong Recommendation, Moderate-Quality Evidence) In adults with SCA who have severe symptomatic chronic anemia that interferes with daily activities or quality of life, treat with hydroxyurea. (Strong Recommendation, Moderate-Quality Evidence).

 

read more